Aurora Cannabis (ACB)
Market Price (3/28/2026): $3.23 | Market Cap: $183.1 MilSector: Health Care | Industry: Pharmaceuticals
Aurora Cannabis (ACB)
Market Price (3/28/2026): $3.23Market Cap: $183.1 MilSector: Health CareIndustry: Pharmaceuticals
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -47% | Weak multi-year price returns2Y Excs Rtn is -56%, 3Y Excs Rtn is -117% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -55 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -15% |
| Megatrend and thematic driversMegatrends include Health & Wellness Trends. Themes include Nutritional Supplements, Functional Foods & Beverages, and Organic & Natural Products. | Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 12.17, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 13% | Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -2.6%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -8.4% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -51% | ||
| Key risksACB key risks include [1] significant financial distress, Show more. |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -47% |
| Megatrend and thematic driversMegatrends include Health & Wellness Trends. Themes include Nutritional Supplements, Functional Foods & Beverages, and Organic & Natural Products. |
| Weak multi-year price returns2Y Excs Rtn is -56%, 3Y Excs Rtn is -117% |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 12.17, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 13% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -55 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -15% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -2.6%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -8.4% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -51% |
| Key risksACB key risks include [1] significant financial distress, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Aurora Cannabis (ACB) stock has lost about 30% since 11/30/2025 because of the following key factors:
1. Aurora Cannabis missed analysts' earnings and revenue estimates for Q3 2026, which covered the period ending December 31, 2025. The company reported an earnings per share (EPS) of $0.09, falling short of the consensus estimate of $0.10 by $0.01. Quarterly revenue reached $68.59 million, also below the $92.39 million consensus. This performance contributed to an approximately 8% drop in the stock price following the earnings announcement in February 2026. Additionally, an earlier weak outlook for Q1 2026, predicting lower expected sales from Poland, may have also influenced investor sentiment.
2. The broader cannabis sector experienced significant weakness and volatility during the period. The industry overall faced "sector related volatility" and a "sharp decline in the overall trading for most top marijuana stocks." This widespread downturn was characterized by pricing volatility, oversupply-driven compression in mature markets, and increased reliance on discounts by retailers to stimulate sales. Furthermore, the number of active cannabis business licenses in the U.S. declined, with cultivation licenses specifically dropping by 24% over the past two years, reflecting a prolonged contraction within the regulated cannabis industry.
Show more
1. Aurora Cannabis missed analysts' earnings and revenue estimates for Q3 2026, which covered the period ending December 31, 2025. The company reported an earnings per share (EPS) of $0.09, falling short of the consensus estimate of $0.10 by $0.01. Quarterly revenue reached $68.59 million, also below the $92.39 million consensus. This performance contributed to an approximately 8% drop in the stock price following the earnings announcement in February 2026. Additionally, an earlier weak outlook for Q1 2026, predicting lower expected sales from Poland, may have also influenced investor sentiment.
2. The broader cannabis sector experienced significant weakness and volatility during the period. The industry overall faced "sector related volatility" and a "sharp decline in the overall trading for most top marijuana stocks." This widespread downturn was characterized by pricing volatility, oversupply-driven compression in mature markets, and increased reliance on discounts by retailers to stimulate sales. Furthermore, the number of active cannabis business licenses in the U.S. declined, with cultivation licenses specifically dropping by 24% over the past two years, reflecting a prolonged contraction within the regulated cannabis industry.
Show more
Stock Movement Drivers
Fundamental Drivers
The -30.4% change in ACB stock from 11/30/2025 to 3/27/2026 was primarily driven by a -31.3% change in the company's P/S Multiple.| (LTM values as of) | 11302025 | 3272026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.60 | 3.20 | -30.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 367 | 373 | 1.6% |
| P/S Multiple | 0.7 | 0.5 | -31.3% |
| Shares Outstanding (Mil) | 56 | 57 | -0.4% |
| Cumulative Contribution | -30.4% |
Market Drivers
11/30/2025 to 3/27/2026| Return | Correlation | |
|---|---|---|
| ACB | -30.4% | |
| Market (SPY) | -5.3% | 17.4% |
| Sector (XLV) | -8.7% | 4.1% |
Fundamental Drivers
The -41.0% change in ACB stock from 8/31/2025 to 3/27/2026 was primarily driven by a -42.9% change in the company's P/S Multiple.| (LTM values as of) | 8312025 | 3272026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.42 | 3.20 | -41.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 358 | 373 | 4.3% |
| P/S Multiple | 0.9 | 0.5 | -42.9% |
| Shares Outstanding (Mil) | 56 | 57 | -0.8% |
| Cumulative Contribution | -41.0% |
Market Drivers
8/31/2025 to 3/27/2026| Return | Correlation | |
|---|---|---|
| ACB | -41.0% | |
| Market (SPY) | 0.6% | 27.3% |
| Sector (XLV) | 5.2% | 8.0% |
Fundamental Drivers
The -37.3% change in ACB stock from 2/28/2025 to 3/27/2026 was primarily driven by a -44.4% change in the company's P/S Multiple.| (LTM values as of) | 2282025 | 3272026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.10 | 3.20 | -37.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 320 | 373 | 16.5% |
| P/S Multiple | 0.9 | 0.5 | -44.4% |
| Shares Outstanding (Mil) | 55 | 57 | -3.2% |
| Cumulative Contribution | -37.3% |
Market Drivers
2/28/2025 to 3/27/2026| Return | Correlation | |
|---|---|---|
| ACB | -37.3% | |
| Market (SPY) | 9.8% | 35.7% |
| Sector (XLV) | -2.1% | 21.0% |
Fundamental Drivers
The -61.7% change in ACB stock from 2/28/2023 to 3/27/2026 was primarily driven by a -62.3% change in the company's P/S Multiple.| (LTM values as of) | 2282023 | 3272026 | Change |
|---|---|---|---|
| Stock Price ($) | 8.35 | 3.20 | -61.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 212 | 373 | 76.3% |
| P/S Multiple | 1.3 | 0.5 | -62.3% |
| Shares Outstanding (Mil) | 33 | 57 | -42.4% |
| Cumulative Contribution | -61.7% |
Market Drivers
2/28/2023 to 3/27/2026| Return | Correlation | |
|---|---|---|
| ACB | -61.7% | |
| Market (SPY) | 69.4% | 22.8% |
| Sector (XLV) | 18.4% | 15.5% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ACB Return | -35% | -83% | -48% | -11% | -1% | -21% | -96% |
| Peers Return | -6% | -45% | -51% | -12% | -13% | -19% | -84% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -5% | 72% |
Monthly Win Rates [3] | |||||||
| ACB Win Rate | 25% | 33% | 50% | 25% | 50% | 0% | |
| Peers Win Rate | 25% | 25% | 37% | 37% | 37% | 20% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| ACB Max Drawdown | -35% | -84% | -54% | -39% | -19% | -23% | |
| Peers Max Drawdown | -22% | -48% | -62% | -26% | -52% | -21% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -5% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: TLRY, CGC, CRON, SNDL, OGI.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/27/2026 (YTD)
How Low Can It Go
| Event | ACB | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -97.8% | -25.4% |
| % Gain to Breakeven | 4398.3% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -85.2% | -33.9% |
| % Gain to Breakeven | 576.8% | 51.3% |
| Time to Breakeven | Not Fully Recovered days | 148 days |
| 2018 Correction | ||
| % Loss | -80.8% | -19.8% |
| % Gain to Breakeven | 421.5% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
Compare to TLRY, CGC, CRON, SNDL, OGI
In The Past
Aurora Cannabis's stock fell -97.8% during the 2022 Inflation Shock from a high on 2/10/2021. A -97.8% loss requires a 4398.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Aurora Cannabis (ACB)
Aurora Cannabis Inc. produces, distributes, and sells cannabis and cannabis derivative products in Canada and internationally. It also engages in facility engineering and design, cannabis breeding, research, production, derivatives, product development, wholesale, and retail distribution activities. The company produces various strains of dried cannabis, cannabis oil and capsules, and topical kits for medical patients. It also sells vaporizers; consumable vaporizer accessories; and herb mills for using CanniMed herbal cannabis products, as well as grinders and vaporizer lockable containers. In addition, the company engages in the development of medical cannabis products at various stages of development, including oral, topical, edible, and inhalable products; and operation of CanvasRX, a network of cannabis counseling and outreach centers. Further, it provides patient counselling services; design and construction services; and cannabis analytical product testing services. The company's brand portfolio includes Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock, and WMMC. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.
AI Analysis | Feedback
Like Anheuser-Busch InBev, but for cannabis products.
A consumer goods giant similar to Procter & Gamble, but specializing in cannabis and related accessories.
A diversified beverage company akin to Constellation Brands, but entirely dedicated to cannabis.
AI Analysis | Feedback
```html- Dried Cannabis: Aurora Cannabis offers various strains of dried cannabis for medical and recreational markets.
- Cannabis Oils & Capsules: The company produces concentrated cannabis oils and capsules for medical patients.
- Topical Cannabis Kits: Aurora develops and sells topical cannabis kits designed for external application.
- Advanced Medical Cannabis Products: The company is involved in the development of oral, topical, edible, and inhalable medical cannabis products.
- Cannabis Accessories: Aurora sells a variety of accessories including vaporizers, herb mills, grinders, and lockable containers.
- Facility Engineering & Design Services: Aurora provides design and construction services for cannabis cultivation and processing facilities.
- Cannabis Breeding & Research: The company engages in activities focused on cannabis breeding and scientific research.
- Wholesale & Retail Distribution: Aurora handles both wholesale and retail distribution of its cannabis and derivative products.
- Patient Counseling Services: Through CanvasRX, the company offers counseling and outreach services to cannabis patients.
- Cannabis Analytical Product Testing: Aurora provides services for analytical testing of cannabis products to ensure quality and safety.
AI Analysis | Feedback
Aurora Cannabis (ACB) sells primarily to individuals. Its major customer categories are:
-
Medical Patients: Individuals who purchase various forms of cannabis, including dried flower, cannabis oil, capsules, and topical kits, for therapeutic purposes. These patients often access products directly from Aurora or through its affiliated network of cannabis counseling and outreach centers, such as CanvasRX, and benefit from patient counselling services.
-
Recreational Consumers (Adult-Use Market): Adults in Canada who purchase Aurora's wide range of cannabis and cannabis derivative products for recreational purposes. These products, sold under various brands like Aurora, Aurora Drift, San Rafael '71, and Daily Special, are typically distributed through provincially regulated retail channels.
AI Analysis | Feedback
nullAI Analysis | Feedback
Miguel Martin, Chief Executive Officer, Executive Chairman
Miguel Martin was appointed Chief Executive Officer of Aurora Cannabis in September 2020 and took on the additional role of Executive Chairman in September 2024. He previously served as Chief Commercial Officer for Aurora since July 2020. Prior to joining Aurora, Mr. Martin was the President and CEO of Reliva, a prominent CBD company. His career also includes serving as President / General Manager of Logic Technology Development LLC, a manufacturer of electronic cigarettes, and as VP and General Manager of Altria Consumer Engagement Services. He has a 25-year background in consumer packaged goods and highly regulated industries. Mr. Martin has been instrumental in leading Aurora's "transformation" with a focus on high-margin global medical cannabis.
Simona King, Chief Financial Officer
Simona King was appointed Chief Financial Officer of Aurora Cannabis, effective February 21, 2024. She brings over 25 years of progressive finance leadership experience. Before joining Aurora, Ms. King served nearly 20 years at Bristol Myers-Squibb, a multinational pharmaceutical company, where she held increasingly senior finance roles, including divisional CFO of enterprise services and head of finance, corporate financial planning and analysis. Most recently, she was the CFO of Passage Bio from 2021 through July 2023. Her experience includes growing businesses, improving operational efficiencies, and leading global financial organizations.
Alex Miller, Executive Vice President, Operations & Supply Chain
Alex Miller serves as the Executive Vice President of Operations & Supply Chain at Aurora Cannabis. This role is crucial for managing the company's supply chain, particularly given its strategic focus on high-margin global medical cannabis.
Andre Jerome, Executive Vice President, Global Business Development
Andre Jerome is the Executive Vice President of Global Business Development at Aurora Cannabis. His role involves driving growth and expanding the company's presence in international markets.
Jillian Swainson, Chief Legal Officer
Jillian Swainson holds the position of Chief Legal Officer at Aurora Cannabis. She is responsible for the company's legal affairs, ensuring compliance and guiding legal strategy in the evolving cannabis industry.
AI Analysis | Feedback
The key risks to Aurora Cannabis (ACB) are primarily its financial health, the evolving and challenging regulatory landscape, and intense competition, particularly from the illicit market.- Financial Health and Profitability Challenges: Aurora Cannabis has faced significant financial challenges, including consistent net losses, declining revenue growth, and a substantial drop in its stock value. The company's Altman Z-Score indicates financial distress, implying a potential risk of bankruptcy within the next two years. While the company has pivoted to focus on high-margin medical cannabis sales, it operates in a challenging financial environment with negative profitability metrics.
- Regulatory Risks: The company is exposed to regulatory changes both internationally and domestically. Upcoming regulatory changes in Germany, which is Aurora's largest international market, pose a direct threat that could significantly impact sales in its core growth engine. In Canada, the broader cannabis industry, including Aurora, has contended with over-regulation, onerous taxation policies, and restrictions on marketing and advertising, which hinder market development and profitability. Furthermore, Aurora has a negligible presence in the U.S. market, limiting its ability to capitalize on potential regulatory changes there.
- Competition from the Illicit Market and Price Compression: The legal cannabis market in Canada struggles to compete effectively with a thriving illicit market. Legal products often face higher prices due to taxes and regulatory compliance costs, and consumers sometimes perceive the quality to be lower than black market alternatives. This intense competition has led to significant price compression in the Canadian adult-use market, eroding profit margins for companies like Aurora.
AI Analysis | Feedback
The emerging threat to Aurora Cannabis is the development and scaling of **bio-engineered cannabinoids (e.g., produced through yeast fermentation or other synthetic biology methods)**. This technology has the potential to fundamentally disrupt the traditional plant-based cannabis cultivation model by offering a potentially cheaper, more consistent, and purer source of cannabinoids for a wide range of products (like edibles, beverages, oils, and pharmaceuticals). If successful at a commercial scale, this could make large-scale agricultural cannabis cultivation, which Aurora heavily relies on, less competitive or even obsolete for certain product categories, similar to how new manufacturing processes can displace older, more resource-intensive ones.
AI Analysis | Feedback
Aurora Cannabis Inc. operates in significant and growing addressable markets for its main products and services, primarily focused on cannabis and cannabis derivative products for both medical and recreational use across Canada and internationally.
Global Addressable Markets
- The global legal cannabis market was estimated at USD 69.78 billion in 2024 and is projected to reach USD 216.76 billion by 2033, demonstrating a Compound Annual Growth Rate (CAGR) of 13.49% from 2025 to 2033. Another estimate valued the global cannabis market at USD 49.8 billion in 2024, with projections to reach USD 173.68 billion by 2032, growing at a CAGR of 16.9% between 2025 and 2032.
- The global medical cannabis market size was estimated at USD 14.34 billion in 2024 and is anticipated to reach approximately USD 52.23 billion by 2034, with a CAGR of 13.8% from 2025 to 2034. Another report valued it at USD 25.86 billion in 2024, expecting it to reach USD 133.73 billion by 2032, with a CAGR of 22.8% from 2025 to 2032.
- The global recreational cannabis market is expected to grow from USD 20 billion in 2022 to USD 123.83 billion by 2032, at a CAGR of 20% from 2023-2032.
Canadian Addressable Markets
- The Canadian legal cannabis market, encompassing both medical and recreational sales, was valued at USD 3.25 billion in 2024 and is projected to reach USD 5.79 billion by 2030, with a CAGR of 12.0% from 2025 to 2030. Total cannabis sales in Canada reached approximately C$5.5 billion in the fiscal year ending March 31, 2025, and C$5.62 billion for the full calendar year 2025.
- The Canadian medical cannabis industry was worth an estimated CA$573 million in 2023-24, comprising CA$355 million in domestic sales and approximately CA$218 million in exports. The market is projected to reach USD 4,569.5 million (approximately C$6.26 billion at current exchange rates) by 2030, growing at a CAGR of 15.5% from 2024 to 2030.
- Canadian recreational cannabis sales were worth CA$5.07 billion (approximately $3.8 billion USD) in 2023. Recreational sales were approximately C$5.4 billion in both 2023 and 2024, and exceeded C$5.6 billion in 2025. Projections also suggest recreational cannabis sales could reach C$7.9 billion in 2025 and C$12.2 billion in 2030.
Cannabis Derivatives Market (Canada)
- In the fiscal year ending March 31, 2025, "Inhaled Cannabis Extracts," including vape pens, hash, wax, and rosin, grew to C$1.7 billion in Canada.
- Ingested cannabis extracts, such as oils, capsules, and sprays, reached C$170.4 million in Canada for the fiscal year ending March 31, 2025.
- By 2025, extracts are anticipated to grow from 10% to 37% of the Canadian direct cannabis market, while edibles are expected to rise from 5% to 12%. The CBD segment held the largest market share in 2025 within the Canadian legal cannabis market.
AI Analysis | Feedback
Aurora Cannabis Inc. (NASDAQ: ACB) is strategically positioning itself for future revenue growth over the next 2-3 years by focusing on the high-margin global medical cannabis market and enhancing operational efficiencies. The company's primary drivers of future revenue growth include:
- International Medical Cannabis Market Expansion: Aurora Cannabis is heavily focused on expanding its presence and market share in key international medical cannabis markets. This includes established strongholds and growth initiatives in Europe, particularly Germany and Poland, and the Asia-Pacific region, specifically Australia and New Zealand. For example, Aurora maintains a leading position in Germany, where cannabis imports are estimated to double in 2025, and holds the number one market position in Poland. The company continues to strengthen its position in the Australian medical cannabis market, including the 2024 acquisition of MedReleaf Australia and recent portfolio expansions. Aurora is also exploring potential new markets such as Ukraine and Turkey. This international expansion is driven by the higher margins and more stable pricing found in regulated medical cannabis markets compared to recreational markets.
- Product Innovation and Proprietary Genetics: Aurora is investing in its science and innovation program, particularly through its Aurora Coast breeding facility, to develop new proprietary cannabis genetics (cultivars). These efforts aim to create high-potency, high-yield, and uniquely profiled cultivars that cater to patient demands and reduce production costs. The introduction of new high-potency cultivars has already contributed to medical cannabis growth in European markets. The company is also expanding its product formats, such as new cannabis oil ranges in Australia, to meet diverse patient needs.
- Operational Efficiency and Strategic Portfolio Optimization: The company is enhancing its operational efficiency and optimizing its production facilities to reduce costs and improve scalability, which directly contributes to higher adjusted gross margins. A significant part of this strategy involves divesting from lower-margin segments, such as certain Canadian consumer cannabis markets and its plant propagation business, to reallocate resources towards its higher-margin global medical cannabis operations. This strategic shift allows Aurora to focus on its core profitable medical cannabis business, which currently accounts for a significant portion of its total revenue and adjusted gross profit.
- Strategic Partnerships and Mergers & Acquisitions (M&A): Aurora considers strategic partnerships and potential mergers and acquisitions as crucial to its long-term growth strategy. These initiatives enable the company to access new technologies, distribution networks, or market segments. The company has established an at-the-market equity program of up to $100 million USD to fund strategic and accretive purposes, including increasing cultivation capacity and potential M&A opportunities within the global medical cannabis sector.
AI Analysis | Feedback
Share Repurchases
- Between December 2021 and December 2022, Aurora Cannabis repurchased approximately CA$316.5 million (US$235 million) principal amount of its convertible senior notes, resulting in annual cash interest savings of about CA$17.4 million (US$12.9 million).
- In March 2023, the company repurchased an additional CA$46.6 million (US$34.3 million) of its convertible senior notes, which saved CA$2.6 million in annualized interest payments.
Share Issuance
- Aurora Cannabis's shares outstanding significantly increased from 0.017 billion in December 2020 to an estimated 0.057 billion in December 2025, indicating substantial share issuance.
- The company executed a 1-for-10 reverse stock split in February 2024.
- On February 4, 2026, Aurora Cannabis established an "at-the-market" (ATM) offering program to issue up to U.S.$100 million of common shares from treasury, with proceeds aimed at strategic uses including increased cultivation capacity and M&A.
Outbound Investments
- Aurora Cannabis acquired MedReleaf Australia for $44.7 million (AUS$51.0 million), contributing to global medical cannabis growth in Q3 FY25 (quarter ending December 31, 2024).
Capital Expenditures
- In the last 12 months, capital expenditures were -$15.81 million.
- The average capital expenditures over the past five years have been approximately $54.01 million.
- A primary focus of capital allocation has been on investing in European and Australian GMP certified manufacturing and distribution facilities to support international growth.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| With Aurora Cannabis Stock Sliding, Have You Assessed The Risk? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to ACB.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 1.91 |
| Mkt Cap | 0.3 |
| Rev LTM | 327 |
| Op Inc LTM | -35 |
| FCF LTM | -34 |
| FCF 3Y Avg | -45 |
| CFO LTM | -15 |
| CFO 3Y Avg | -25 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 9.7% |
| Rev Chg 3Y Avg | 15.5% |
| Rev Chg Q | 5.0% |
| QoQ Delta Rev Chg LTM | 1.2% |
| Op Mgn LTM | -11.1% |
| Op Mgn 3Y Avg | -16.9% |
| QoQ Delta Op Mgn LTM | 1.7% |
| CFO/Rev LTM | -3.0% |
| CFO/Rev 3Y Avg | -6.1% |
| FCF/Rev LTM | -8.3% |
| FCF/Rev 3Y Avg | -15.9% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.3 |
| P/S | 0.7 |
| P/EBIT | -8.7 |
| P/E | -1.5 |
| P/CFO | -6.5 |
| Total Yield | -25.5% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -23.3% |
| D/E | 0.5 |
| Net D/E | -0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -16.0% |
| 3M Rtn | -25.9% |
| 6M Rtn | -33.7% |
| 12M Rtn | -12.1% |
| 3Y Rtn | -50.4% |
| 1M Excs Rtn | -9.6% |
| 3M Excs Rtn | -19.9% |
| 6M Excs Rtn | -31.5% |
| 12M Excs Rtn | -19.3% |
| 3Y Excs Rtn | -113.6% |
Price Behavior
Price Behavior
| Market Price | $3.20 | |
| Market Cap ($ Bil) | 0.2 | |
| First Trading Date | 10/23/2018 | |
| Distance from 52W High | -48.6% | |
| 50 Days | 200 Days | |
| DMA Price | $3.71 | $4.57 |
| DMA Trend | down | down |
| Distance from DMA | -13.8% | -30.0% |
| 3M | 1YR | |
| Volatility | 50.2% | 69.9% |
| Downside Capture | 1.81 | 1.51 |
| Upside Capture | 194.68 | 139.84 |
| Correlation (SPY) | 49.2% | 33.5% |
ACB Betas & Captures as of 2/28/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.74 | 2.00 | 0.43 | 1.57 | 1.26 | 1.42 |
| Up Beta | 1.37 | 0.94 | 0.41 | 0.53 | 0.96 | 1.00 |
| Down Beta | 2.82 | 1.77 | -0.10 | 2.45 | 1.25 | 1.15 |
| Up Capture | 275% | 208% | 16% | 78% | 154% | 361% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 10 | 18 | 26 | 51 | 114 | 331 |
| Down Capture | 340% | 265% | 133% | 179% | 141% | 112% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 11 | 22 | 34 | 71 | 132 | 410 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ACB | |
|---|---|---|---|---|
| ACB | -26.9% | 70.0% | -0.17 | - |
| Sector ETF (XLV) | 0.3% | 17.6% | -0.13 | 20.0% |
| Equity (SPY) | 14.5% | 18.9% | 0.59 | 33.5% |
| Gold (GLD) | 50.2% | 27.7% | 1.46 | 14.1% |
| Commodities (DBC) | 17.8% | 17.6% | 0.85 | 17.8% |
| Real Estate (VNQ) | 0.4% | 16.4% | -0.15 | 21.1% |
| Bitcoin (BTCUSD) | -21.0% | 44.0% | -0.41 | 34.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ACB | |
|---|---|---|---|---|
| ACB | -49.4% | 90.0% | -0.38 | - |
| Sector ETF (XLV) | 6.0% | 14.5% | 0.23 | 18.9% |
| Equity (SPY) | 11.8% | 17.0% | 0.54 | 30.8% |
| Gold (GLD) | 20.7% | 17.7% | 0.96 | 7.5% |
| Commodities (DBC) | 11.6% | 18.9% | 0.50 | 10.3% |
| Real Estate (VNQ) | 3.0% | 18.8% | 0.07 | 24.4% |
| Bitcoin (BTCUSD) | 4.7% | 56.6% | 0.30 | 17.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ACB | |
|---|---|---|---|---|
| ACB | -43.2% | 101.3% | -0.32 | - |
| Sector ETF (XLV) | 9.7% | 16.5% | 0.48 | 19.4% |
| Equity (SPY) | 14.0% | 17.9% | 0.67 | 29.1% |
| Gold (GLD) | 13.3% | 15.8% | 0.70 | 5.0% |
| Commodities (DBC) | 8.2% | 17.6% | 0.39 | 14.0% |
| Real Estate (VNQ) | 4.7% | 20.7% | 0.19 | 24.3% |
| Bitcoin (BTCUSD) | 66.9% | 66.8% | 1.06 | 15.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 02/04/2026 | 6-K |
| 09/30/2025 | 11/05/2025 | 6-K |
| 06/30/2025 | 08/06/2025 | 6-K |
| 03/31/2025 | 06/18/2025 | 40-F |
| 12/31/2024 | 02/05/2025 | 6-K |
| 09/30/2024 | 11/06/2024 | 6-K |
| 06/30/2024 | 08/07/2024 | 6-K |
| 03/31/2024 | 06/20/2024 | 40-F |
| 12/31/2023 | 02/08/2024 | 6-K |
| 09/30/2023 | 11/09/2023 | 6-K |
| 06/30/2023 | 08/10/2023 | 6-K |
| 03/31/2023 | 06/14/2023 | 40-F |
| 12/31/2022 | 02/10/2023 | 6-K |
| 09/30/2022 | 11/14/2022 | 6-K |
| 06/30/2022 | 09/21/2022 | 40-F |
| 03/31/2022 | 05/13/2022 | 6-K |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.